Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Accelerate to discover
Related topics
Cardiomyocyte isolation using Cellenion’s cellenONE instrument
Mar 24, 2023
The cellenONE platform is ideal for the isolation of fragile and heterogeneous cell size populations, such as...
ACCELA educational webinar: Unlocking Spatial Biology with RareCyte Orion
Mar 16, 2023
Experience Spatial Biology with Orion Multiplex Imaging. Orion is a benchtop, high...
Recorded webinar: Anesthesia Considerations in Small Animal Imaging
Mar 13, 2023
Anesthesia settings and operation of Optical Imaging Systems: methods, animal handling, safety and regulatory...
Introducing Cytek Human Leukocyte Kit, the first ever 15-color lyse no-wash assay
Mar 13, 2023
This kit has been designed to enumerate all major leukocyte subsets and it mirrors and expands on those identified in a...
Immunofluorescence Imaging for Rare Cell Detection with CyteFinder II
Mar 7, 2023
CyteFinder II Instruments are high speed, whole slide imaging systems with options for liquid biopsy analysis and...
NanoCellect Webinar: Optimizing the Cell Line Development Process with Microfluidic Cell Sorting
Mar 3, 2023
Single-cell selection and cloning are required for bioengineering workflows such as antibody production, cell therapy,...
New Kit for Bacterial analysis expands capability of Guava Muse flow cytometer
Feb 20, 2023
With the Guava Muse cell analyzer, you can now achieve highly quantitative results at a fraction of the price, effort,...
Flash news - did you know, that you can use Singulator S100 also for plant research?
Feb 10, 2023
In this short TechNote you can find how Singulator can help the data quality in Single cell sequencing - now even in...
Jun 13, 2017
Pancreatic cancer has a remarkably high mortality rate, primarily due to late detection of the disease (Siegel et al. 2016). Therefore, efforts to reduce the incidence of pancreatic cancer may provide significant benefit in people at risk of developing the disease. Obese and diabetic individuals are known to have an increased risk of pancreatic cancer (Bardeesy et al. 2002).
Therefore, this study sought to determine whether aspartame or stevia, two commonly used artificial sweeteners, provide benefit in mice with pancreatic cancer. Lead author Dr. James Dooley and colleagues at the University of Leuven in Belgium published their paper entitled, “No Effect of Dietary Aspartame or Stevia on Pancreatic Acinar Carcinoma Development, Growth, or Induced Mortality in a Murine Model,” in Frontiers of Oncology in February of 2017.
The role of artificial sweeteners in cancer risk remains controversial (Tandel 2011), with some studies proposing anti-tumor effects while others purport carcinogenic properties of these chemicals. “With strong links to diabetes, glucose consumption and obesity, pancreatic cancer remains one of the strongest candidates to detect an oncogenic role, either promoting or suppressive, of artificial sweeteners,” the authors begin.
In order to test the potential role of these artificial sweeteners in pancreatic cancer disease progression, the authors allowed mice to drink water with or without aspartame or stevia present. The researchers used a Bruker Biospin 9.4 T Biospec small animal MR scanner to perform magnetic resonance imaging (MRI) in order to locate tumors in the mice and follow their progression over time.
Related technologies: Magnetic resonance imaging
Get more info
Brand profile
Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
More info at:
www.bruker.com